相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cabazitaxel in Metastatic Prostate Cancer
Vincenzo Di Nunno et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
ALDH as a Stem Cell Marker in Solid Tumors
Marie E. Toledo-Guzman et al.
CURRENT STEM CELL RESEARCH & THERAPY (2019)
The small molecule WNT/β-catenin inhibitor CWP232291 blocks the growth of castration-resistant prostate cancer by activating the endoplasmic reticulum stress pathway (vol 38, 342, 2019)
Sahyun Pak et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Hypoxia inducible factors in the tumor microenvironment as therapeutic targets of cancer stem cells
Farnaz Hajizadeh et al.
LIFE SCIENCES (2019)
Role of hypoxia in cancer therapy by regulating the tumor microenvironment
Xinming Jing et al.
MOLECULAR CANCER (2019)
ATP-dependent thermostabilization of human P-glycoprotein (ABCB1) is blocked by modulators
Sabrina Lusvarghi et al.
BIOCHEMICAL JOURNAL (2019)
Reversal of sorafenib resistance in hepatocellular carcinoma: epigenetically regulated disruption of 14-3-3η/hypoxia-inducible factor-1α
Yongxin Qiu et al.
CELL DEATH DISCOVERY (2019)
Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy
Ali Alqahtani et al.
FUTURE SCIENCE OA (2019)
Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment
Deepali Waghray et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia
Tamara Maes et al.
CANCER CELL (2018)
Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors
Jay H. Kalin et al.
NATURE COMMUNICATIONS (2018)
1830OLiquid biopsy as tool to monitor and predict clinical benefit from chemotherapy (CT) and immunotherapy (IT) in advanced non-small cell lung cancer (aNSCLC): A prospective study
L Bonanno et al.
ANNALS OF ONCOLOGY (2018)
Chemoprevention of Preclinical Breast and Lung Cancer with the Bromodomain Inhibitor I-BET 762
Di Zhang et al.
CANCER PREVENTION RESEARCH (2018)
Use of retinoic acid/aldehyde dehydrogenase pathway as potential targeted therapy against cancer stem cells
Jan S. Moreb et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
Preclinical activity of CPI-0610, a novel small-molecule bromodomain and extra-terminal protein inhibitor in the therapy of multiple myeloma
K. T. Siu et al.
LEUKEMIA (2017)
Advances toward LSD1 inhibitors for cancer therapy
Xiaoli Fu et al.
FUTURE MEDICINAL CHEMISTRY (2017)
Molecular genetics and targeted therapy of WNT-related human diseases
Masuko Katoh et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2017)
Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review)
Masaru Katoh
INTERNATIONAL JOURNAL OF ONCOLOGY (2017)
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
Tsukasa Shibue et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC
Lauren MacDonagh et al.
ONCOTARGET (2017)
Thalidezine, a novel AMPK activator, eliminates apoptosis-resistant cancer cells through energy-mediated autophagic cell death
Betty Yuen Kwan Law et al.
ONCOTARGET (2017)
Cancer Stem Cells and Their Microenvironment: Biology and Therapeutic Implications
Eunice Yuen-Ting Lau et al.
STEM CELLS INTERNATIONAL (2017)
Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer
Meng Zhang et al.
CANCER BIOLOGY & MEDICINE (2017)
A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors
Antonio Jimeno et al.
CLINICAL CANCER RESEARCH (2017)
Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic Strategies
Mai H. Bui et al.
CANCER RESEARCH (2017)
Epigenetics and Cancer Stem Cells: Unleashing, Hijacking, and Restricting Cellular Plasticity
Elanor N. Wainwright et al.
TRENDS IN CANCER (2017)
Wnt addiction of genetically defined cancers reversed by PORCN inhibition
B. Madan et al.
ONCOGENE (2016)
BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer
Yuhki Yokoyama et al.
CANCER RESEARCH (2016)
Molecular mechanisms for tumour resistance to chemotherapy
Shu-Ting Pan et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2016)
The synthetic ajoene analog SPA3015 induces apoptotic cell death through crosstalk between NF-κB and PPARγ in multidrug-resistant cancer cells
Jee Won Hwang et al.
FOOD AND CHEMICAL TOXICOLOGY (2016)
Antiangiogenesis and vascular disrupting agents in cancer: circumventing resistance and augmenting their therapeutic utility
Anne Close
FUTURE MEDICINAL CHEMISTRY (2016)
Hypoxia-NOTCH1-SOX2 signaling is important for maintaining cancer stem cells in ovarian cancer
Eun Jin Seo et al.
ONCOTARGET (2016)
A Histone Deacetylase Inhibitor Suppresses Epithelial-Mesenchymal Transition and Attenuates Chemoresistance in Biliary Tract Cancer
Takuya Sakamoto et al.
PLOS ONE (2016)
Cancer stem cell targeting: Are we there yet?
Yuchae Jung et al.
ARCHIVES OF PHARMACAL RESEARCH (2015)
A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 inhibitors in SCLC
Helai P. Mohammad et al.
CANCER CELL (2015)
All-trans retinoic acid downregulates ALDH1-mediated stemness and inhibits tumour formation in ovarian cancer cells
Ming-Jer Young et al.
CARCINOGENESIS (2015)
The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs
Michela Boi et al.
CLINICAL CANCER RESEARCH (2015)
Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update
Naoko Takebe et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells
Marie-Magdelaine Coude et al.
ONCOTARGET (2015)
Overcoming Multidrug Resistance in Cancer Stem Cells
Karobi Moitra
BIOMED RESEARCH INTERNATIONAL (2015)
Phase 2 Study of RO4929097, a Gamma-Secretase Inhibitor, in Metastatic Melanoma: SWOG 0933
Sylvia M. Lee et al.
CANCER (2015)
AMPK Inhibits the Stimulatory Effects of TGF-β on Smad2/3 Activity, Cell Migration, and Epithelial-to-Mesenchymal Transition
Hui Lin et al.
MOLECULAR PHARMACOLOGY (2015)
Epithelial ovarian cancer stem cells: underlying complexity of a simple paradigm
Kenneth Garson et al.
REPRODUCTION (2015)
Epigenetic drugs against cancer: an evolving landscape
Antonella Di Costanzo et al.
ARCHIVES OF TOXICOLOGY (2014)
Targeting histone lysine demethylases - Progress, challenges, and the future
Cyrille C. Thinnes et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2014)
The Cancer Stem Cell Marker Aldehyde Dehydrogenase Is Required to Maintain a Drug-Tolerant Tumor Cell Subpopulation
Debasish Raha et al.
CANCER RESEARCH (2014)
Strategies to overcome the barrier: use of nanoparticles as carriers and modulators of barrier properties
Ralf Rempe et al.
CELL AND TISSUE RESEARCH (2014)
Metastatic Stem Cells: Sources, Niches, and Vital Pathways
Thordur Oskarsson et al.
CELL STEM CELL (2014)
Monitoring hypoxia and vasculature during bevacizumab treatment in a murine colorectal cancer model
L. Heijmen et al.
CONTRAST MEDIA & MOLECULAR IMAGING (2014)
MicroRNAs in Cancer Stem Cells: New Regulators of Stemness
Fei Xing et al.
CURRENT PHARMACEUTICAL DESIGN (2014)
The BET Bromodomain Inhibitor I-BET151 Acts Downstream of Smoothened Protein to Abrogate the Growth of Hedgehog Protein-driven Cancers
Jun Long et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Discovery and Exploitation of Novel Targets by Approved Drugs
Luc Dirix
JOURNAL OF CLINICAL ONCOLOGY (2014)
Metformin reverses multidrug resistance and epithelial-mesenchymal transition (EMT) via activating AMP-activated protein kinase (AMPK) in human breast cancer cells
Chen Qu et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2014)
Oncogenic roles of EMT-inducing transcription factors
Alain Puisieux et al.
NATURE CELL BIOLOGY (2014)
Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia
E. J. Gang et al.
ONCOGENE (2014)
Snail Contributes to the Maintenance of Stem Cell-Like Phenotype Cells in Human Pancreatic Cancer
Wei Zhou et al.
PLOS ONE (2014)
Inducible In Vivo Silencing of Brd4 Identifies Potential Toxicities of Sustained BET Protein Inhibition
Jessica E. Bolden et al.
CELL REPORTS (2014)
Nanoparticles for Combination Drug Therapy
Liang Ma et al.
ACS NANO (2013)
ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors
Cheng-Po Huang et al.
CANCER LETTERS (2013)
A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics
Stephanie D. Steichen et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2013)
Metabolic roles of AMPK and metformin in cancer cells
Yeon Kyung Choi et al.
MOLECULES AND CELLS (2013)
Effect of Doxorubicin/Pluronic SP1049C on Tumorigenicity, Aggressiveness, DNA Methylation and Stem Cell Markers in Murine Leukemia
Daria Y. Alakhova et al.
PLOS ONE (2013)
Targeting Wnt-driven cancer through the inhibition of Porcupine by LGK974
Jun Liu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
P-glycoprotein Inhibition for Optimal Drug Delivery
Md. Lutful Amin
DRUG TARGET INSIGHTS (2013)
The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness
Bin Bao et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2012)
Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds
A. Palmeira et al.
CURRENT MEDICINAL CHEMISTRY (2012)
Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics
Su-Ni Tang et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Enhanced apoptosis of ovarian cancer cells via nanocarrier-mediated codelivery of siRNA and doxorubicin
Seyin Zou et al.
INTERNATIONAL JOURNAL OF NANOMEDICINE (2012)
Nanotechnology applied to overcome tumor drug resistance
Zibin Gao et al.
JOURNAL OF CONTROLLED RELEASE (2012)
Epigenetic alterations involved in cancer stem cell reprogramming
Purificacion Munoz et al.
MOLECULAR ONCOLOGY (2012)
Traceable Multifunctional Micellar Nanocarriers for Cancer-Targeted Co-delivery of MDR-1 siRNA and Doxorubicin
Xiao-Bing Xiong et al.
ACS NANO (2011)
Effects of Baicalein on the Pharmacokinetics of Tamoxifen and its Main Metabolite, 4-Hydroxytamoxifen, in Rats: Possible Role of Cytochrome P450 3A4 and P-glycoprotein inhibition by Baicalein
Cheng Li et al.
ARCHIVES OF PHARMACAL RESEARCH (2011)
Conformational Analysis of Human ATP-binding Cassette Transporter ABCB1 in Lipid Nanodiscs and Inhibition by the Antibodies MRK16 and UIC2
Tasha K. Ritchie et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
HDAC Inhibitor Vorinostat Enhances the Antitumor Effect of Gefitinib in Squamous Cell Carcinoma of Head and Neck by Modulating ErbB Receptor Expression and Reverting EMT
Francesca Bruzzese et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2011)
Genome-scale epigenetic reprogramming during epithelial-to-mesenchymal transition
Oliver G. McDonald et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2011)
Sonic Hedgehog Pathway Is Essential for Maintenance of Cancer Stem-Like Cells in Human Gastric Cancer
Zhou Song et al.
PLOS ONE (2011)
Quiescent, Slow-Cycling StemCell Populations in Cancer: A Review of the Evidence and Discussion of Significance
Nathan Moore et al.
JOURNAL OF ONCOLOGY (2011)
Cancer stem-like cells can be isolated with drug selection in human ovarian cancer cell line SKOV3
Li Ma et al.
ACTA BIOCHIMICA ET BIOPHYSICA SINICA (2010)
Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1
Zhongxing Liang et al.
BIOCHEMICAL PHARMACOLOGY (2010)
Biochemical, Structural, and Biological Evaluation of Tranylcypromine Derivatives as Inhibitors of Histone Demethylases LSD1 and LSD2
Claudia Binda et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2010)
IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer
I. Ibanez de Caceres et al.
ONCOGENE (2010)
Activation of the hedgehog-signaling pathway in human cancer and the clinical implications
L. Yang et al.
ONCOGENE (2010)
Normal stem cells and cancer stem cells: similar and different
Mark Shackleton
SEMINARS IN CANCER BIOLOGY (2010)
Reversal of ABC Drug Transporter-Mediated Multidrug Resistance in Cancer Cells: Evaluation of Current Strategies
Chung-Pu Wu et al.
Current Molecular Pharmacology (2010)
MicroRNA Regulation of Cancer Stem Cells and Therapeutic Implications
Jeffrey T. DeSano et al.
AAPS JOURNAL (2009)
γ-Secretase Inhibitors Abrogate Oxaliplatin-Induced Activation of the Notch-1 Signaling Pathway in Colon Cancer Cells Resulting in Enhanced Chemosensitivity
Raymond D. Meng et al.
CANCER RESEARCH (2009)
ABCG2 is related with the grade of glioma and resistance to mitoxantone, a chemotherapeutic drug for glioma
Yao Jin et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2009)
OPINION Is NF-κB a good target for cancer therapy? Hopes and pitfalls
Veronique Baud et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/β-catenin pathway
M. Flahaut et al.
ONCOGENE (2009)
Cancer stem cell epigenetics and chemoresistance
Francesco Crea et al.
EPIGENOMICS (2009)
Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells
Wen Yang et al.
CANCER RESEARCH (2008)
Transfer of Drug Resistance Genes into Hematopoietic Stem Cells for Marrow Protection
Joseph R. Bertino
ONCOLOGIST (2008)
EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer
Alexandra M. Pietersen et al.
BREAST CANCER RESEARCH (2008)
Ixabepilone, first in a new class of antineoplastic agents: The natural epothilones and their analogues
Monica N. Fornier
CLINICAL BREAST CANCER (2007)
Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport
J. Sims-Mourtada et al.
ONCOGENE (2007)
A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer
Leena Gandhi et al.
CANCER (2007)
Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies
Michael R. Horsman et al.
CANCER RESEARCH (2006)
Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells
John P. Chute et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Allosteric modulation of the human P-glycoprotein involves conformational changes mimicking catalytic transition intermediates
Pratiti Ghosh et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2006)
Gene therapy with drug resistance genes
M Zaboikin et al.
CANCER GENE THERAPY (2006)
Targeting multidrug resistance in cancer
G Szakács et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
A formylated hexapeptide ligand mimics the ability of Wnt-5a to impair migration of human breast epithelial cells
A Säfholm et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Hematopoietic stem cell gene therapy with drug resistance genes: an update
T Budak-Alpdogan et al.
CANCER GENE THERAPY (2005)
A distinct side population of cells with high drug efflux capacity in human tumor cells
C Hirschmann-Jax et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Differential effects of toremifene on doxorubicin, vinblastine and Tc-99m-sestamibi in P-glycoprotein-expressing breast and head and neck cancer cell lines
M Mubashar et al.
ACTA ONCOLOGICA (2004)
Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells
G Dontu et al.
BREAST CANCER RESEARCH (2004)
P-glycoprotein: from genomics to mechanism
SV Ambudkar et al.
ONCOGENE (2003)
Transcriptional regulation of ABC drug transporters
KW Scotto
ONCOGENE (2003)
Pluronic® block copolymers for overcoming drug resistance in cancer
AV Kabanov et al.
ADVANCED DRUG DELIVERY REVIEWS (2002)
Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933
L van Zuylen et al.
EUROPEAN JOURNAL OF CANCER (2002)
Multidrug resistance in cancer: Role of ATP-dependent transporters
MM Gottesman et al.
NATURE REVIEWS CANCER (2002)
Modulation by LY335979 of P-glycoprotein function in multidrug-resistant cell lines and human natural killer cells
LJ Green et al.
BIOCHEMICAL PHARMACOLOGY (2001)
Phase I study of cinchonine, a multidrug resistance reversing agent, combined with the CHVP regimen in relapsed and refractory lymphoproliferative syndromes
E Solary et al.
LEUKEMIA (2000)
The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo
B Shi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2000)
Multidrug resistance (MDR) in cancer - Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs
R Krishna et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2000)
分享论文
